- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 5.00 Å
- Oligo State
- hetero-3-3-3-3-3-1-1-mer
- Ligands
- 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.8: 7 residues within 4Å:- Chain A: N.226, L.229, S.255, S.404, S.405, N.406
- Ligands: NAG-NAG-BMA-MAN.6
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.12: 8 residues within 4Å:- Chain B: V.218, L.225, N.226, N.339, G.341, C.403, S.404, S.405
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:G.341
- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- NAG- GAL- NAG- MAN- FUC: beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)]alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-NAG-GAL-NAG-MAN-FUC.21: 17 residues within 4Å:- Chain E: R.122, E.123, N.126
- Chain P: V.1, D.25, F.26, P.27, K.30, Y.31, R.97, F.99, Q.100, E.101, S.102
- Chain Q: N.32, F.59, S.60
5 PLIP interactions:4 interactions with chain P, 1 interactions with chain Q- Hydrogen bonds: P:V.1, P:V.1, P:D.25, P:F.26, P:R.97, P:Y.31, P:E.101, P:E.101, P:E.101, Q:N.32
- 1 x NAG- NAG- BMA- MAN- NAG- GAL- MAN- FUC: beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-6)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-NAG-GAL-MAN-FUC.22: 14 residues within 4Å:- Chain E: N.100, S.102, Y.127, L.130
- Chain P: R.18, D.53, A.54, W.55, L.68, S.70, R.71, Y.79, E.81, P.105
6 PLIP interactions:5 interactions with chain P, 1 interactions with chain E- Hydrophobic interactions: P:P.105, E:Y.127
- Hydrogen bonds: P:R.18, P:S.70, P:R.71, P:R.71, P:E.81
- 43 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.24: 2 residues within 4Å:- Chain A: N.124, V.133
Ligand excluded by PLIPNAG.25: 2 residues within 4Å:- Chain A: R.156, N.161
Ligand excluded by PLIPNAG.26: 3 residues within 4Å:- Chain A: N.198, T.200, S.238
Ligand excluded by PLIPNAG.27: 5 residues within 4Å:- Chain A: N.259, T.261, H.293, N.295, V.373
Ligand excluded by PLIPNAG.28: 1 residues within 4Å:- Chain A: N.354
Ligand excluded by PLIPNAG.29: 2 residues within 4Å:- Chain A: E.57, N.58
Ligand excluded by PLIPNAG.30: 2 residues within 4Å:- Chain A: N.152, T.153
Ligand excluded by PLIPNAG.31: 2 residues within 4Å:- Chain A: G.317, N.318
Ligand excluded by PLIPNAG.32: 2 residues within 4Å:- Chain A: N.324, R.427
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain B: N.124, Q.134, K.135
Ligand excluded by PLIPNAG.34: 3 residues within 4Å:- Chain B: L.104, N.120, L.139
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain B: N.240, T.242, D.243
Ligand excluded by PLIPNAG.36: 5 residues within 4Å:- Chain B: E.232, E.233, N.253, K.254, Q.307
Ligand excluded by PLIPNAG.37: 6 residues within 4Å:- Chain B: T.261, H.293, N.295, T.371, V.373, R.402
Ligand excluded by PLIPNAG.38: 7 residues within 4Å:- Chain B: E.257, N.259, N.295, I.296, S.297, T.371, R.402
Ligand excluded by PLIPNAG.39: 2 residues within 4Å:- Chain B: N.265, Q.400
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain B: Q.351, N.354
Ligand excluded by PLIPNAG.41: 1 residues within 4Å:- Chain B: N.324
Ligand excluded by PLIPNAG.42: 5 residues within 4Å:- Chain B: N.198, T.200, S.238, A.239, F.241
Ligand excluded by PLIPNAG.43: 2 residues within 4Å:- Chain B: N.318, K.319
Ligand excluded by PLIPNAG.44: 1 residues within 4Å:- Chain B: N.152
Ligand excluded by PLIPNAG.45: 3 residues within 4Å:- Chain B: R.156, N.161, T.162
Ligand excluded by PLIPNAG.46: 1 residues within 4Å:- Chain B: N.100
Ligand excluded by PLIPNAG.47: 3 residues within 4Å:- Chain B: L.229, S.255, N.406
Ligand excluded by PLIPNAG.48: 6 residues within 4Å:- Chain B: E.57, N.58
- Chain F: G.16, S.17
- Chain M: G.8, G.9
Ligand excluded by PLIPNAG.49: 2 residues within 4Å:- Chain C: N.100, N.152
Ligand excluded by PLIPNAG.50: 2 residues within 4Å:- Chain C: N.198, T.200
Ligand excluded by PLIPNAG.51: 3 residues within 4Å:- Chain C: S.255, N.406
- Ligands: NAG-NAG-BMA-MAN-MAN.16
Ligand excluded by PLIPNAG.52: 3 residues within 4Å:- Chain C: N.240, T.242, D.243
Ligand excluded by PLIPNAG.53: 2 residues within 4Å:- Chain C: N.120, Y.137
Ligand excluded by PLIPNAG.54: 1 residues within 4Å:- Chain C: N.152
Ligand excluded by PLIPNAG.55: 5 residues within 4Å:- Chain C: N.259, N.295, I.296, S.297, R.402
Ligand excluded by PLIPNAG.56: 2 residues within 4Å:- Chain C: N.265, I.286
Ligand excluded by PLIPNAG.57: 5 residues within 4Å:- Chain C: H.293, N.295, T.371, V.373, R.402
Ligand excluded by PLIPNAG.58: 6 residues within 4Å:- Chain C: E.232, V.234, N.253, K.254, Q.307, K.311
Ligand excluded by PLIPNAG.59: 3 residues within 4Å:- Chain C: Q.351, N.354
- Ligands: NAG-NAG.18
Ligand excluded by PLIPNAG.60: 2 residues within 4Å:- Chain C: N.318, K.319
Ligand excluded by PLIPNAG.61: 4 residues within 4Å:- Chain C: N.324, H.325, I.425, R.427
Ligand excluded by PLIPNAG.62: 1 residues within 4Å:- Chain D: N.114
Ligand excluded by PLIPNAG.63: 3 residues within 4Å:- Chain F: N.105, K.106, Q.110
Ligand excluded by PLIPNAG.64: 2 residues within 4Å:- Chain F: N.114
- Chain M: V.5
Ligand excluded by PLIPNAG.65: 1 residues within 4Å:- Chain F: N.126
Ligand excluded by PLIPNAG.66: 3 residues within 4Å:- Chain F: N.100, S.102, L.130
Ligand excluded by PLIP- 3 x 44E: (2R)-3-(phosphonooxy)propane-1,2-diyl dihexanoate(Non-covalent)
44E.67: 4 residues within 4Å:- Chain G: S.109
- Chain H: L.26, R.27, Y.30
2 PLIP interactions:2 interactions with chain H- Hydrogen bonds: H:Y.30, H:Y.30
44E.68: 4 residues within 4Å:- Chain J: S.109
- Chain K: L.26, R.27, Y.30
1 PLIP interactions:1 interactions with chain K- Hydrogen bonds: K:Y.30
44E.69: 4 residues within 4Å:- Chain M: S.109
- Chain N: L.26, R.27, Y.30
2 PLIP interactions:2 interactions with chain N- Hydrogen bonds: N:Y.30, N:Y.30
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Rantalainen, K. et al., HIV-1 Envelope and MPER Antibody Structures in Lipid Assemblies. Cell Rep (2020)
- Release Date
- 2020-04-22
- Peptides
- Envelope glycoprotein gp120: ABC
Envelope glycoprotein gp41: DEF
Antibody 10E8 Fab heavy chain: GJM
Antibody 10E8 Fab light chain: HKN
MPER peptide: ILO
Antibody PGT151 Fab heavy chain: P
Antibody PGT151 Fab light chain: Q - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
EC
CD
DE
BF
FG
HJ
KM
MH
LK
NN
OI
GL
IO
JP
PQ
Q
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 5.00 Å
- Oligo State
- hetero-3-3-3-3-3-1-1-mer
- Ligands
- 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- NAG- GAL- NAG- MAN- FUC: beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)]alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- NAG- GAL- MAN- FUC: beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-6)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 43 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x 44E: (2R)-3-(phosphonooxy)propane-1,2-diyl dihexanoate(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Rantalainen, K. et al., HIV-1 Envelope and MPER Antibody Structures in Lipid Assemblies. Cell Rep (2020)
- Release Date
- 2020-04-22
- Peptides
- Envelope glycoprotein gp120: ABC
Envelope glycoprotein gp41: DEF
Antibody 10E8 Fab heavy chain: GJM
Antibody 10E8 Fab light chain: HKN
MPER peptide: ILO
Antibody PGT151 Fab heavy chain: P
Antibody PGT151 Fab light chain: Q - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
EC
CD
DE
BF
FG
HJ
KM
MH
LK
NN
OI
GL
IO
JP
PQ
Q